The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Cannabis as a risk factor for psychosis: systematic review
Abstract
Various lines of evidence suggest an association between cannabis and psychosis. Five years ago, the only significant case-control study addressing this question was the Swedish Conscript Cohort. Within the last few years, other studies have emerged, allowing the evidence for cannabis as a risk factor to be more systematically reviewed and assessed. Using specific search criteria on Embase, PsychINFO and Medline, all studies examining cannabis as an independent risk factor for schizophrenia, psychosis or psychotic symptoms, published between January 1966 and January 2004, were examined. Additional studies were also reviewed from references found in retrieved articles, reviews, and a cited reference search (ISI-Web of Science). Studies selected for meta-analysis included: (i) case-control studies where exposure to cannabis preceded the onset of schizophrenia or schizophrenia-like psychosis and (ii) cohort studies of healthy individuals recruited before the median age of illness onset, with cannabis exposure determined prospectively and blind to eventual diagnosis. Studies of psychotic symptoms were also tabulated for further discussion. Eleven studies were identified examining the relationship between cannabis use and psychosis. Seven were included in the meta-analysis, with a derived odds ratio (fixed effects) of 2·9 (95% confidence interval = 2.4-3.6). No evidence of publication bias or heterogeneity was found. Early use of cannabis did appear to increase the risk of psychosis. For psychotic symptoms, a dose-related effect of cannabis use was seen, with vulnerable groups including individuals who used cannabis during adolescence, those who had previously experienced psychotic symptoms, and those at high genetic risk of developing schizophrenia. In conclusion, the available evidence supports the hypothesis that cannabis is an independent risk factor, both for psychosis and the development of psychotic symptoms. Addressing cannabis use, particularly in vulnerable populations, is likely to have beneficial effects on psychiatric morbidity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Evidence from most case-control and cross-sectional studies support an association between cannabis use and schizophrenia (4-6) and psychotic symptoms (7)(8)(9).”
From Association Between Cannabis and Psychosis: Epidemiologic Evidence (2016) · cites this paper as [6]
In the citing paper
“Capsaicin patches are proposed as second-line for peripheral neuropathic pain because of high quality of evidence, but modest effect size, training requirements, and potential safety concerns on sensation with long-term use.65”
From Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis (2015) · cites this paper as [65]
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002) · BMJ · doi:10.1136/bmj.325.7374.1212 · Cited by 1,399
Cannabis and schizophrenia. A longitudinal study of Swedish conscripts
Andréasson, S., Engström, A., Allebeck, P., & Rydberg, U. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92620-1 · Cited by 1,166
Cannabis use and psychosis: A longitudinal population-based study
van Os, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf043 · Cited by 928
Causal association between cannabis and psychosis: examination of the evidence
Arseneault, L., Cannon, M., Witton, J., & Murray, R. M. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.2.110 · Cited by 913
Zammit, S., Allebeck, P., Andreasson, S., Lundberg, I., & Lewis, G. (2002) · BMJ · doi:10.1136/bmj.325.7374.1199 · Cited by 871
Sex Differences in the Risk of Schizophrenia: Evidence From Meta-analysis
Aleman, A., Kahn, R. S., & Selten, J.-P. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.565 · Cited by 818 · cited 1×
“Patterns of drug misuse, particularly cannabis, may help to explain the finding of an earlier age of onset of schizophrenia being observed in male compared to female patients in the published literature from the last two decades (Aleman et al., 2003).”
Result
Research works printed but not linked: 3
- 10.1080/j.1440-1614.2000.00736.x · doi:10.1080/j.1440-1614.2000.00736.x · Paper page
- Potvin S, 2003, Encephale, 29, 193
- Smit F, 2003, Ned Tijdschr Geneeskd, 147, 2178
Cited by
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224
Pharmacologic management of neuropathic pain: Evidence-based recommendations
Dworkin, R. H., O’Connor, A. B., Backonja, M., Farrar, J. T., Finnerup, N. B., Jensen, T. S., Kalso, E. A., Loeser, J. D., Miaskowski, C., Nurmikko, T. J., et al. (2007) · Pain · doi:10.1016/j.pain.2007.08.033 · Cited by 2,126
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Cannon, T. D., Cadenhead, K., Cornblatt, B., Woods, S. W., Addington, J., Walker, E., Seidman, L. J., Perkins, D., Tsuang, M., McGlashan, T., et al. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.3 · Cited by 1,269
“Included in the list of potentialpredictorswerevariables foundtobeassociatedwithrisk of conversion to psychosis in previous studies of smaller samples, including genetic risk for schizophrenia,(8,21,22) severityofprodromalsymptoms,(11)severityofnonspecificsymptoms,(19) social and role functioning,(19,23,24) and substa…”
Background
Metadata
- Authors
- Semple, D. M., McIntosh, A. M., & Lawrie, S. M.
- Affiliations
- University of Edinburgh (GB)
- Corresponding author
- Semple, David M.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2005-03
- Volume
- 19
- Issue
- 2
- Pages
- 187-194
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2129378060
- Cited by
- 420
- References
- 45
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 12 · 2023: 13 · 2022: 9 · 2021: 23 · 2020: 17 · 2019: 8 · 2018: 15 · 2017: 21 · 2016: 29 · 2015: 26 · 2014: 25 · 2013: 22 · 2012: 26
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychopathy, Forensic Psychiatry, Sexual Offending
- Keywords
- cannabis use, psychosis, schizophrenia, psychotic symptoms, risk factors, adolescent cannabis use, dose-response relationship, genetic risk, psychiatric morbidity
- MeSH terms
- Adolescent, Adult, Dose-Response Relationship, Drug, Female, Humans, Longitudinal Studies, Male, Marijuana Smoking, Middle Aged, Psychotic Disorders, Risk Factors, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cannabis as a risk factor for psychosis: systematic review. https://app.cochat.ai/papers/10.1177/0269881105049040
- The paper
- Semple, D. M., McIntosh, A. M., & Lawrie, S. M. (2005). Cannabis as a risk factor for psychosis: systematic review. Journal of Psychopharmacology. https://doi.org/10.1177/0269881105049040
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.